Alexion Pharma (ALXN) Tops Q3 EPS by 11c

Alexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.27, $0.11 better than the analyst estimate of $1.16. Revenue for the quarter came in at $555.1 million versus the consensus estimate of $541.93 million.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance